Dsc Advisors, L.P. Bristol Myers Squibb CO Transaction History

Dsc Advisors, L.P.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $35,293 - $38,870	-486 Reduced 12.29%	3,467 $267,000
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $243,030 - $291,415	3,953 New	3,953 $289,000
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $4.92 Million - $5.74 Million	-91,763 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $593,889 - $695,664	10,037 Added 12.28%	91,763 $5.43 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $896,642 - $976,443	14,483 Added 21.54%	81,726 $5.46 Million
Q1 2021 May 14, 2021	BUY	$59.34 - $66.74 $390,931 - $439,683	6,588 Added 10.86%	67,243 $4.25 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $14.4 Million - $16.3 Million	-249,787 Reduced 80.46%	60,655 $3.76 Million
Q3 2020 Nov 16, 2020	BUY	$57.43 - $63.64 $14.4 Million - $15.9 Million	250,235 Added 415.62%	310,442 $4.21 Million
Q2 2020 Aug 14, 2020	BUY	$54.82 - $64.09 $542,005 - $633,657	9,887 Added 19.65%	60,207 $3.54 Million
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $970,641 - $1.41 Million	-20,919 Reduced 29.36%	50,320 $2.81 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $3.45 Million - $4.5 Million	70,156 Added 6477.93%	71,239 $4.57 Million
Q3 2019 Nov 14, 2019	BUY	$42.77 - $50.71 $46,319 - $54,918	1,083 New	1,083 $55,000
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $3.45 Million - $4.11 Million	-76,476 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $3.73 Million - $4.84 Million	76,476 New	76,476 $3.98 Million

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Dsc Advisors, L.P., based on Form 13F filings with the SEC.

Stay updated on Dsc Advisors, L.P. with notifications on news.